Analyst consensus rating
Medline Analyst Rating: Buy
Direct answer
Medline's consensus rating is Buy.
26 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $45.31.
Forecast evidence checked November 12, 2026.
Get free Medline email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $42.16
- Average price target
- $45.31
- High price target
- $55.00
- Low price target
- $34.00
- Low target gap
- -19.4%
- Target upside
- +7.5%
- High target gap
- +30.5%
- Target range width
- 49.8%
- Consensus rating
- Buy
- Analysts
- 26
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Medline?
Medline has a verified Buy consensus. The same dataset has an average price target of $45.31.
How far are Medline's low and high targets from the recorded price?
The low target implies -19.4%, while the high target implies +30.5%.
How many analysts are included in Medline's consensus?
The verified consensus includes 26 analysts.
How is Medline's target upside or downside calculated?
The average target of $45.31 is divided by the recorded price of $42.16, then one is subtracted to produce +7.5%. This does not guarantee a future return.
When was Medline's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.